このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Break It Up: A Study Evaluating Breaking Up Daily Sedentary Behavior in Youth

Background:

Some studies have found that people can better process sugars when they take walking breaks. Studies have also found that children's attention and memory may improve after exercise. It is not known if short walking breaks have the same effects. Researchers want to study if breaking up sitting with walking for 6 days helps children s bodies use sugars and improves concentration.

Objectives:

To learn if breaking up sedentary (low-activity) time with short walking breaks over 6 days affects how children s bodies use sugar. To learn if breaking up sedentary time changes children s attention, memory, feelings, activity, or eating.

Eligibility:

Children ages 7-11 in general good health

Design:

Participants will be screened with:

  • Medical history
  • Physical exam
  • Fasting blood tests. On 2 out of 7 total study visits, participants cannot eat or drink after 10 p.m. the night before.
  • Full-body X-ray
  • EKG (Electronic signals that record heart function through stickers)
  • Treadmill exercise. Heart, blood pressure, and oxygen will be monitored.
  • Questions about the child s health, socialization, and activity, and parent s education and economic status
  • Picture vocabulary test
  • Dietician meeting (Questions about eating habits)

Participants will have visits on 6 consecutive days. Over that time, they will wear 2 devices to monitor blood sugar and activity (even while at home).

Participants will have 5 after-school visits. These include:

  • Health check
  • Snack plus food for the next 24 hours
  • Activity monitored
  • 3-hour sitting tests. Participants will do non-active things. Some will have 3-minute walks every 30 minutes.
  • Cognitive tests and questions about mood and anxiety are given on days #1 & 5.

Participants will fast before the last visit in the morning. They will have:

  • 9 blood draws by IV catheter. Participants will drink sugar water.
  • Sitting test
  • Activity monitored
  • Meal (food buffet)

調査の概要

詳細な説明

Background:

Sedentary behavior is defined as a set of low-intensity activities involving limited body movement (e.g.: TV viewing, prolonged sitting). Some studies have found higher levels of childhood sedentary behavior predict higher body mass index (BMI) and metabolic abnormalities. We and others have found that interrupting sitting with short, 2-3 minute bouts of moderate activity (walking) can improve glucose tolerance during a single session. Thus, interrupting sedentary behavior may be an intervention strategy to reduce health risks.

Objective:

We propose to conduct a randomized pilot study to assess whether interrupting sedentary behavior for 6 consecutive days provides sustained improvement in carbohydrate metabolism without negatively impacting executive function, attention, mood, anxiety, dietary

intake or usual physical activity.

Design & Population:

Using a randomized parallel group design, children, ages 7-11 years, will complete an assigned randomized condition of either 6 consecutive days of 3 hours of monitored sedentary activity (sitting) or 6 consecutive days of 3 hours of interrupted sitting (in which they will be prompted to walk for 3 minutes every 30 minutes).

Outcome measures:

Twenty-four-hour continuous glucose monitoring and postprandial insulin incremental area under the curve (iAUC) on post-condition oral glucose tolerance testing will be the primary measures. Secondary measures include: postprandial glucose iAUC, executive function, attention, mood, anxiety, dietary intake, and free-living physical activity.

Impact:

This project will investigate if consecutive daily interruption of sitting behaviors improves glucose tolerance, a potential negative health consequences of sedentary behavior in children. If repeatedly interrupting sitting with short bouts has sustained beneficial effects among children, interventions examining the frequency, duration, and intensity of such interruptions could be developed for use in the community setting. Thus, these results have the potential to provide insight into novel behavioral intervention targets in youth.

研究の種類

介入

入学 (実際)

129

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • National Institutes of Health Clinical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

7年~11年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

  • INCLUSION CRITERIA:

Participants will qualify for the study if they meet the following criteria:

  1. Good general health.
  2. Age greater than or equal to 7 and less than 12 years.
  3. Fasting plasma glucose less than 100 mg/dL
  4. Body mass index (BMI) greater than or equal to the 5th percentile, as determined by the CDC age- and sex- specific growth charts.

EXCLUSION CRITERIA:

Participants will be excluded from the study for:

  1. Significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion.
  2. Evidence of impaired glucose tolerance or type 2 diabetes, including fasting plasma glucose greater than or equal to 100 mg/dL.
  3. Presence of other endocrinologic disorders leading to obesity (e.g.: Cushing Syndrome).
  4. Participants who have, or whose parent/guardians have, current substance abuse or a psychiatric disorder or other condition that, in the opinion of the investigators, would impede competence, compliance, or prevent the completion of the study.
  5. Participants who have, or are currently receiving, anti-psychotic drugs that would affect metabolism, cognitive outcomes, and body habitus.
  6. Participants receiving medical treatment other than diet for hypertension or dyslipidemia.
  7. Participants with precocious puberty and/or receiving androgen and estrogen therapy.
  8. Participants currently taking medications for ADHD, or any disorder or use of medications known to affect body composition or weight including but not limited to glucocorticoids or other steroid compounds.
  9. Presence of pre-existing neurocognitive disabilities, or an age-adjusted score below 85 on the Picture Vocabulary Test at the screening visit.
  10. Presence of food allergies, such as peanut/tree nut, dairy, soy or any other food allergy or personal dietary restrictions that would preclude participant from consuming the daily diet or the buffet.
  11. Presence of significant skin disease or allergy to adhesive material prohibiting placement of a continuous glucose monitor.
  12. Participants unable or unwilling to abstain from acetaminophen, ascorbic acid, or salicylic acid during study duration.
  13. Participant does not speak fluent English.
  14. Participant is or becomes pregnant.
  15. Participant has an ambulatory impairment

OPTIONAL MRS SUPPLEMENTAL ARM

INCLUSION CRITERIA

(a) Participants will qualify for the study if they qualify for the primary Break It Up! study.

EXCLUSION CRITERIA

  1. Cannot have MRI scanning. Some of the reasons a child might not be able to have MRI include:

    • Implanted cardiac pacemaker or defibrillator
    • Cochlear Implants
    • Ocular foreign body (e.g. metal shavings)
    • Embedded shrapnel fragments
    • Central nervous system aneurysm clips
    • Implanted neural stimulator
    • Medical infusion pumps
    • Any implanted device that is incompatible with MRI.
  2. Is not likely to tolerate an MRI scan. Examples of medical conditions that would make it difficult to undergo MRI include severe anxiety (nervousness) or hyperactivity which make it hard for your child to lay flat for the study.
  3. Requires sedation for MRI studies.
  4. Has a condition that makes entry into the scanner difficult (e.g. weight over 550 lbs, claustrophobia, etc.).
  5. Has severe back-pain or motion disorders that make it hard for a child to lie on his/her back within the MRI scanner and hold still for the scan.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Sedentary
(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
実験的:Walking bouts
Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Insulin iAUC Obtained During the Oral Glucose Tolerance Test at the Final Experimental Visit.
時間枠:test day 6
Insulin integrated area under the curve (iAUC) as a marker of glucose metabolism on OGTT during test day #6, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion
test day 6

二次結果の測定

結果測定
メジャーの説明
時間枠
Glucose iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention.
時間枠:test day 6
Integrated area under the curve (iAUC) for glucose values during the oral glucose tolerance test, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion
test day 6
C-Peptide iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention.
時間枠:test day 6
Integrated area under the curve (iAUC) for C-Peptide values during the oral glucose tolerance test, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion
test day 6
Free Fatty Acid iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention.
時間枠:test day 6
Integrated area under the curve (iAUC) for Free Fatty Acid values during the oral glucose tolerance test, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion
test day 6
Daily Physical Activity (Step Counts/Min) During Intervention.
時間枠:test days 1-6
Mean 3-dimensional activity during the 3 hours of intervention from all days (step counts per minute)
test days 1-6
Daily Physical Activity (3-dimensional Activity Counts/Day) Outside of the Intervention.
時間枠:test days 1-6
Mean total daily 3-dimensional activity counts during the 21 hours without intervention on days 1-6 (activity counts/21 hours) from triaxial write accelerometers worn at home. Note: these are not "step counts" but total 3D activity counts because motion of the wrist at times other than walking are also recorded. There is no simple way to convert these counts to step counts.
test days 1-6
Energy Intake at the Final Test Meal.
時間枠:test day 6
Total energy intake (kcal) during buffet meal immediately after the end of intervention
test day 6
Percentage Fat Intake at the Final Test Meal.
時間枠:test day 6
Percentage Energy intake from Fat during buffet meal immediately after the end of intervention
test day 6
Percentage Carbohydrate Intake at the Final Test Meal.
時間枠:test day 6
Percentage Energy intake from Carbohydrate during buffet meal immediately after the end of intervention
test day 6
Percentage Protein Intake at the Final Test Meal.
時間枠:test day 6
Percentage Energy intake from Protein during buffet meal immediately after the end of intervention
test day 6

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年7月26日

一次修了 (実際)

2020年6月26日

研究の完了 (実際)

2021年2月23日

試験登録日

最初に提出

2017年7月19日

QC基準を満たした最初の提出物

2017年7月19日

最初の投稿 (実際)

2017年7月21日

学習記録の更新

投稿された最後の更新 (実際)

2021年6月11日

QC基準を満たした最後の更新が送信されました

2021年5月13日

最終確認日

2021年1月4日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 170130
  • 17-CH-0130 (その他の識別子:NIH Clinical Center - protocol number)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Individual level deidentified data for all sociodemographic characteristics and outcomes will be made available after publication of the study primary outcome.

IPD 共有時間枠

Immediately following publication of the primary outcome for 5 years

IPD 共有アクセス基準

A data sharing agreement may have to be negotiated with NICHD. Contact Dr. Jack Yanovski jy15i@nih.gov, 301-496-0858.

IPD 共有サポート情報タイプ

  • 研究プロトコル
  • インフォームド コンセント フォーム (ICF)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する